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Simple Summary: Menopausal hormone therapy (MHT) increases risk of developing breast cancer
(BC), and women are often advised to avoid its use for this reason. In this analysis we examined
the size of this effect using data from a large cohort of women attending breast cancer screening in
Manchester, UK. We additionally explored the extent to which risk from MHT might be modified
by current BMI, early adulthood body mass index (BMI) (age 20 years), and age of first pregnancy.
Identifying modifying effects would help enable better estimation of risk associated with MHT for
an individual woman. Results indicated that women using combined oestrogen and progestagen
MHT were at greater risk than those receiving oestrogen-only MHT. The Relative risk associated
with MHT was less for obese women than non-obese women. After adjustment for current BMI, the
effect of MHT did not appear to be substantially modified by early BMI or age of pregnancy.
Abstract: Menopausal hormone therapy (MHT) has an attenuated effect on breast cancer (BC) risk
amongst heavier women, but there are few data on a potential interaction with early adulthood
body mass index (at age 20 years) and age of first pregnancy. We studied 56,489 women recruited
to the PROCAS (Predicting Risk of Cancer at Screening) study in Manchester UK, 2009-15. Cox
regression models estimated the effect of reported MHT use at entry on breast cancer (BC) risk, and
potential interactions with a. self-reported current body mass index (BMI), b. BMI aged 20 and c. First
pregnancy >30 years or nulliparity compared with first pregnancy <30 years. Analysis was adjusted
for age, height, family history, age of menarche and menopause, menopausal status, oophorectomy,
ethnicity, self-reported exercise and alcohol. With median follow up of 8 years, 1663 breast cancers
occurred. BC risk was elevated amongst current users of combined MHT compared to never users
(Hazard ratioHR 1.64, 95% CI 1.32–2.03), risk was higher than for oestrogen only users (HR 1.03,
95% CI 0.79–1.34). Risk of current MHT was attenuated by current BMI (interaction HR 0.80, 95% CI
0.65–0.99) per 5 unit increase in BMI. There was little evidence of an interaction between MHT use,
breast cancer risk and early and current BMI or with age of first pregnancy.
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1. Introduction
Approximately 80% of women going through the menopause experience symptoms [1].
Menopausal hormone therapy (MHT) is the most effective treatment option. MHT use
halved in the early 2000s as a result of widely publicised associations between MHT use
and increased risk of breast cancer and thromboembolism. Rates stabilised in the 2010s
and currently there are an estimated one million MHT users in the UK each year, rep-
resenting approximately 10% of women passing through the menopause [1]. A recent
meta-analysis based on 58 prospective and retrospective studies, including 568,859 women
and 143,887 breast cancer cases concluded that ever MHT use is associated with increased
breast cancer risk (RR 1.26, 95% CI 1.24–1.28). Risk is higher for current compared to past
users and increased with longer MHT use. Amongst current users, risk is greater with com-
bined (oestrogen plus progestagen) MHT (RR for 5–14 years of use 2.08, 95% CI 2.02–2.15)
compared to oestrogen only MHT (RR 1.33, 95% CI 1.28–1.37). Risk was attenuated
amongst heavier women, particularly for oestrogen-only MHT, with little additional risk
from oestrogen-only MHT in women who were obese [2].
MHT use increases breast cancer risk amongst women in the general population but
also in women with increased risk due to familial cancer [3]. Many women, especially those
at higher risk of breast cancer, are counselled to avoid or minimise MHT use [4]. Guidelines
recommend an individual risk benefit assessment for prescribing MHT [5]. However there
are limited data on whether MHT risk is modified by other patient characteristics which
would help to inform this decision.
Increased body mass index (BMI) after the menopause (RR per 5 BMI units: 1.12,
95% CI 1.09–1.15) and weight gain throughout adult life after the age of 20 (RR per 5 kg:
1.06, 95% CI 1.05–1.08) are consistently associated with increased risk of postmenopausal
breast cancer [6]. In contrast, higher weight during adolescence and early adulthood
(age ≤30 years) are observed to have an inverse effect [7]. High body adiposity in early
adulthood is associated with a reduced risk of postmenopausal (RR per 5 BMI units: 0.82,
95% CI 0.76–0.88) and premenopausal breast cancer (RR per 5 BMI units: 0.82, 95% CI
0.76–0.89) [6]. We recently reported higher BMI in early adulthood (>23.4 kg/m2) negated
the impact on risk of high later attained BMI [8].
Late age of first pregnancy (after the age of 30 years) and nulliparity are associated
with increased risk of breast cancer. Women with first pregnancy after the age of 30
have approximately twice the risk of developing breast cancer compared to women with
first pregnancy before the age of 20, and nulliparous women have a 30% increased risk
compared to parous women [9]. Risks associated with attained adult and early adulthood
weight and age of pregnancy are all in part mediated by different exposure to oestrogen
and progesterone, and may alter the hormone responsiveness of the breast [10]. Thus they
may modify the risk associated with MHT use.
Here we sought to examine the association between combined and oestrogen only
MHT use and breast cancer risk in a cohort of women from the National Health Service
Breast Screening Programme (NHSBSP), in Greater Manchester, UK. We examined whether
BC risk associated with these types of MHT are modified by BMI at study entry (age
46–84 years) and/ or early adulthood BMI (age 20), or age at first pregnancy or nulliparity.
2. Methods
2.1. Population
The Predicting Risk of Cancer At Screening (PROCAS) study has been described in de-
tail elsewhere. In total 57,902 women aged between 46 and 84 years in the National Health
Service Breast Screening programme (NHSBSP) were recruited from five areas of Greater
Manchester (Manchester, Oldham, Salford, Tameside and Trafford) between October 2009
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and June 2015 [11]. Recruitment was carried out in two phases: initially all women who
were invited for three-yearly breast screening (October 2009–October 2012) after which
only women invited to their first screen in the area (mainly aged 46–53 years) were invited
to participate in the study. Participants were invited once during the recruitment period.
During the initial phase uptake to screening was 68% with uptake to PROCAS 37% of
attendees, in the second phase screening uptake was 58% and uptake to PROCAS was 47%
of attendees (screening uptake is lower in first time invitees).
2.2. Data Collection
Data collection was based on a two-page questionnaire, which was sent to participants
with a consent form between their invitations to attend screening and scheduled screening
appointment (Supplementary Materials).
The self-reported questionnaire gathered information on risk factors for breast cancer
including: previous breast cancer diagnosis, breast or ovarian cancer in first and second
degree relatives, hormonal risk factors, including age at menarche, oophorectomy and
hysterectomy, menopausal status, age at menopause, parity and age at first pregnancy,
physical activity levels, alcohol intake and ethnicity. Questions in relation to MHT use
included name of preparation, duration of use and when MHT was last used (if no longer
on MHT). Women were also asked to record their height, current weight and recalled
weight at age 20 as a proxy of early adulthood BMI. Current BMI and BMI at 20 were
calculated from these variables. Completed questionnaires were collated by the study team
and entered into the study database.
2.3. Diagnosis of Breast Cancer
The primary outcome was diagnosis of a new breast cancer (invasive or ductal car-
cinoma in situ), from entry to PROCAS onwards, as identified through the NHSBSP and
the Somerset and North West Cancer Intelligence services. Follow-up (median eight years)
was censored at date of breast cancer diagnosis, date of death, date lost to follow-up, e.g.,
moving out of the area, or date cancer databases were last checked (April 2020). The current
analysis excluded women with breast cancer diagnosed prior to study entry (N = 895).
2.4. MHT Use
MHT use was classed as never, current and former. Never users were women who
indicated they had never been on MHT at any time. Current users were women who
reported they were still on MHT and gave details about length of time on MHT but did
not indicate a time of stopping. Former users were women who reported no longer using
MHT but indicated how long they had been using MHT and time since stopping.
Where women did not provide an MHT name, it was assumed that those who had a
hysterectomy had oestrogen only MHT, whereas women who did not have hysterectomy
had combined (oestrogen plus progestagen) MHT. MHT status was missing for 514 women
who were excluded from any further analyses (Figure 1).
The analyses included pre/peri and postmenopausal women enrolled in the PROCAS
study. Women were considered postmenopausal if they indicated on the questionnaire they
had been through the menopause (i.e., not had period for 12 months) or reported they had
both ovaries removed (surgical menopause) or current use of MHT or age at menopause
was unknown but age at time of questionnaire completion was 55 years or over as based
on criteria defined by Phipps et al. [12].
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Figure 1. Flow diagram: Number of women in the cohort meeting the criteria for inclusion in
the analysis.
2.5. BMI Data
We excluded attained BMI and early BMI values which were >60 or <16 kg/m2. For
current BMI, 3943 were unknown or beyond these cut-offs. For early BMI, 6300 values were
unknown or beyond these cut-offs. Median value of the cohort was assumed for missing
values (total 6.8% for current and 10.9% for BMI at age 20).
2.6. Statistical Analysis
Demographic Characteristics and Breast Cancer Risk Factors amongst MHT Users and
Non-Users
Differences in demographic characteristics and breast cancer risk factors across MHT
groups (never, current, former) were tested using one-way ANOVA and Chi-square tests
where appropriate. Adjusted comparisons of continuous measure used linear regression
(with covariates for age (years), current and early BMI ( kg/m2)).
2.7. MHT Use and BC Risk
Cox (or proportional hazards) regression was used to model the relationship between
MHT use and diagnosis of breast cancer. Follow-up was censored at date of breast cancer,
date of death or date of last follow-up (April 2020). Results were expressed as hazard ratios
(HR) and 95% Wald confidence intervals (95% CI).
Fully adjusted Cox regression models included the following established risk factors
for breast cancer: age (1 year), height (5 cm), BMI (5 units), early BMI (5 units), ethnic-
ity (white/other), age at menarche (1 year), age at first pregnancy (<20, 20–24, 25–29,
30–34, ≥35) years, parity, age at menopause (1 year) menopausal status (pre/peri or post-
menopausal), oophorectomy, self-reported exercise (1 h/week) and alcohol (1 unit/week),
MHT status (current, former, never), MHT type (combined, oestrogen only) and family
history (first or second degree). For the fully adjusted analysis, missing values were im-
puted as the median value of the cohort. We did not include the available mammographic
density data in the models since there is some evidence this may be part of the pathway
for reduced risk alongside higher early BMI [13]. The multiple deprivation score since this
was not included since this was not associated with risk once the variables associated with
this, such as age of pregnancy were included in the model (Table S1a,S1b).
MHT Use, Breast Cancer R sk and Effect Modification by Current BMI and Early BMI and
Age of First Pregnancy
To assess whether current an early BMI modified the relationship between MHT and
the risk of breast cancer the following two way interaction terms were also included in the
fully adjusted models: current/ former MHT use* current BMI * (Table S2a) and current/
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former MHT use* early BMI (Table S2b). We also tested the 3-way interactions: current/
former MHT use*current BMI *early BMI (Table S2c).
For presentation the relationship between MHT use and BC risk was tabulated by
stratifying above and below the median for current (26.4 kg/m2) and early (21.6 kg/m2)
BMI. The reference group was never use of MHT, current BMI below the median and
early BMI below the median. The median was used to dichotomise results and aid with
interpretation (Table 1).
The relationship between late age at first pregnancy and nulliparity, MHT status and
BC risk was assessed using analysis stratified by age at first pregnancy <30 years or a
combined group which included women with first pregnancy ≥30 years or who were
nulliparous (Table 2 and Table S5).
Due to previous known heterogeneity by type of MHT and subtype of breast cancer
we also performed these analyses according to (i) MHT type (combined oestrogen and
progestagen or oestrogen only) (Table 3) and (ii) oestrogen receptor positive breast cancer.
(Table S1c).
Table 1. MHT and BC risk and current and early BMI.
A
MHT use BMI < 26.4 kg/m2 BMI ≥ 26.4 kg/m2
N (%) BC/ no BC HR (95% CI) N (%) BC/no BC HR (95% CI)
Never 474 (2.5)/18,381 (97.5) 1.00 (Ref) 524 (3.2)/16016 (96.8) 1.44 (1.26–1.64)
Former 256 (3.2)/7858 (96.8) 1.12 (0.95–1.32) 251 (3.2)/7508 (96.8) 1.29 (1.09–1.53)
Current 101 (3.9)/2457 (96.1) 1.60 (1.28–1.98) 57 (3.2)/1725 (96.8) 1.45 (1.09–1.92)
B
BMI age 20 < 21.6 kg/m2 BMI age 20 ≥ 21.6 kg/m2
N (%) BC/noBC HR (95% CI) N (%)BC/no BC HR (95% CI)
Never 439 (3.0)/14,292 (97.0) 1.00 (Ref) 559 (2.7)/20,105 (97.3) 0.85 (0.75–0.97)
Former 235 (3.3)/6878 (96.7) 0.98 (0.83–1.16) 272 (3.1)/8488 0.89 (0.75–1.05)
Current 80 (4.0)/1943 (96.0) 1.37 (1.08–1.75) 78 (3.4)/2239 (96.6) 1.11 (0.86–1.41)
C
BMI age 20 < 21.6 kg/m2 BMI age 20 ≥ 21.6 kg/m2
N (%) BC/no BC HR (95% CI) N (%) BC/no BC HR (95% CI)
Never BMI < 26.4 kg/m2 259 (2.6)/9737 (97.4) 1.00 (Ref) 139 (2.2)/6171 (97.8) 0.86 (0.70–1.06)
Never BMI ≥ 26.4 kg/m2 180 (3.8)/4555 (96.2) 1.53 (1.26–1.85) 420 (2.9)/13,934 (97.1) 1.20 (1.02–1.40)
Former BMI < 26.4 kg/m2 142 (3.2)/4249 (96.8) 1.12 (0.90–1.38) 83 (3.0)/2726 (97.0) 1.03 (0.80–1.33)
Former BMI ≥ 26.4 kg/m2 93 (3.4)/2629 (96.6) 1.23 (0.97–1.57) 189 (3.2)/5762 (96.8) 1.17 (0.96–1.43)
Current BMI < 26.4 kg/m2 54 (3.8)/1385 (96.2) 1.48 (1.10–2.00) 34 (4.0)/808 (96.0) 1.60 (1.12–2.30)
Current BMI ≥ 26.4 kg/m2 558 (95.5)/26 (4.5) 1.84 (1.22–2.76) 1431 (97.0)/44 (3.0) 1.24 (0.90–1.71)
BC breast cancer; Units: age (1 year), BMI (5 BMI units), BMI at age 20 (5 BMI units), height (5 cm), age at menopause (1 year), exercise (1 h
per week), alcohol (1 unit per week), age at menarche (1 year) BMI median: 26.4 kg/m2, BMI20 median: 21.6 kg/m.
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Table 2. MHT status and BC risk and age of pregnancy > 30 and nulliparity.
Age at Pregnancy < 30 Age at Pregnancy ≥ 30
N (%) BC/ no BC HR (95% CI) N (%) BC/ no BC HR (95% CI)
Never 670 (2.7)/24,126 (97.3) 1.00 (Ref) 328 (3.1)/10,271 (96.9) 1.20 (1.05–1.38)
Former 391 (3.1)/12,401 (96.9) 0.99 (0.86–1.13) 116 (3.8)/2965 (96.2) 1.25 (1.02–1.53)
Current 110 (3.5)/3076 (96.5) 1.31 (1.06–1.60) 48 (4.2)/1106 (95.8) 1.64 (1.22–2.20)
Oestrogen only
Age at Pregnancy < 30 Age at Pregnancy ≥ 30
N (%) BC/ no BC HR (95% CI) N (%) BC/ no BC HR (95% CI)
Never 670 (2.7)/24,126 (97.3) 1.00 (Ref) 182 (3.2)/5465 (96.8) 1.28 (1.09–1.51)
Former 151 (2.7)/5399 (97.3) 0.89 (0.73–1.09) 14 (3.5)/390 (96.5) 1.22 (0.71–2.09)
Current 46 (2.6)/1715 (97.4) 0.96 (0.71–1.31) 9 (4.6)/187 (95.4) 1.81 (0.93–3.53)
Combined
Age at Pregnancy < 30 Age at Pregnancy ≥ 30
N (%) no BC/BC HR (95% CI) N (%) no BC/BC HR (95% CI)
Never 670 (2.7)24,126 (97.3) 1.00 (Ref) 182 (3.2)/5465 (96.8) 1.29 (1.09–1.52)
Former 240 (3.3)/7002 (96.7) 1.07 (0.92–1.26) 41 (4.0)/984 (96.0) 1.36 (0.99–1.87)
Current 64 (4.5)/1361 (95.5) 1.74 (1.34–2.25) 16 (4.6)/331 (95.4) 1.90 (1.16–3.13)
BC breast cancer; Units: age (1 year), BMI (5 units), BMI at age 20 (5 units), height (5 cm), age at menopause (1 year), exercise (1 h per week),
alcohol (1 unit per week), age at menarche (1 year).
Table 3. MHT type and BC risk and current and early BMI.
A
BMI < 26.4 kg/m2 BMI ≥ 26.4 kg/m2
N (%) BC/ no BC HR (95% CI) N (%) BC/ no BC HR (95% CI)
Never 439 (3.0)/14,292 (97.0) 1.00 (Ref) 559 (2.7)/20,105 (97.3) 1.48 (1.29–1.69)
Former oestrogen only 79 (2.9)/2664 (97.1) 1.06 (0.81–1.38) 26 (2.1)/1199 (97.9) 1.23 (0.98–1.54)
Former combined 156 (3.6)/4214 (96.4) 1.17 (0.96–1.42) 52 (4.8)/1040 (95.2) 1.40 (1.15–1.69)
Current oestrogen only 37 (4.8)/984 (95.2 1.29 (0.90–1.85) 112 (3.0)/3670 (97.0) 1.16 (0.79–1.70)
Current combined 43 (4.3)/959 (95.7) 1.86 (1.40–2.47) 160 (3.2)/4818 (96.8) 2.11 (1.53–2.92)
B
BMI age 20 < 21.6 kg/m2 BMI age 20 ≥ 21.6 kg/m2
N (%) BC / no BC HR (95% CI) N (%) BC/ no BC HR (95% CI)
Never 439 (3.0)/14,292 (97.0) 1.00 (Ref) 559(2.7)/20,105 (97.3) 0.84 (0.74–0.96)
Former oestrogen only 79 (2.9)/2664 (97.1) 0.85 (0.66–1.10) 112 (3.0)/3670 (97.0) 0.83 (0.66–1.04)
Former combined 156 (3.6)/4214 (96.4) 1.04 (0.86–1.25) 160 (3.2)/4818 (96.8) 0.88 (0.73–1.06)
Current oestrogen only 37 (4.8)/984 (95.2) 1.23 (0.87–1.73) 26 (2.1)/1199 (97.9) 0.67 (0.45–1.00)
Current combined 43 (4.3)/959 (95.7) 1.47 (1.07–2.01) 52 (4.8)/1040 (95.2) 1.54 (1.15–2.06)
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Table 3. Cont.
C
Oestrogen only MHT BMI age 20 < 21.6 kg/m2 BMI age 20 ≥ 21.6 kg/m2
N (%) BC/ no BC HR (95% CI) N (%) BC/ no BC HR (95% CI)
Never BMI < 26.4 kg/m2 259 (2.6)9737 (97.4) 1.00 (Ref) 6171 (97.8)/139 (2.2) 0.86 (0.70–1.05)
Never BMI ≥ 26.4 kg/m2 180 (3.8)/4555 (96.2) 1.54 (1.27–1.86) 420 (2.9)/13,934 (97.1) 1.20 (1.02–1.41)
Former BMI < 26.4 kg/m2 45 (2.9)/1484 (97.1) 1.05 (0.76–1.47) 30 (2.8)/1031 (97.2) 1.00 (0.67–1.48)
Former BMI ≥ 26.4 kg/m2 34 (2.8)/1180 (97.2) 1.04 (0.72–1.50) 82 (3.0)/2639 (97.0) 1.15 (0.87–1.50)
Current BMI < 26.4 kg/m2 23 (3.4)/663 (96.6) 1.33 (0.86–2.05) 11 (2.7)/395 (97.3) 1.06 (0.58–1.95)
Current BMI ≥ 26.4 kg/m2 14 (4.2)/321 (95.8) 1.68 (0.97–2.90) 15 (1.8)/804 (98.2) 0.75 (0.44–1.28)
Combined MHT BMI age 20 < 21.6 kg/m2 BMI age 20 ≥ 21.6 kg/m2
N (%) BC/ no BC HR (95% CI) N (%) BC/ no BC HR (95% CI)
Never BMI < 26.4 kg/m2 259 (2.6)9737 (97.4) 1.00 (Ref) 6171 (97.8)/139 (2.2) 0.86 (0.70–1.05)
Never BMI ≥ 26.4 kg/m2 180 (3.8)/4555 (96.2) 1.52 (1.25–1.84) 420 (2.9)13,934 (97.1) 1.19 (1.01–1.39)
Former BMI < 26.4 kg/m2 97 (3.4)/2765 (96.6) 1.14 (0.90–1.45) 53 (3.0)/1695 (97.0) 1.04 (0.77–1.40)
Former BMI ≥ 26.4 kg/m2 59 (3.9)/1449 (96.1) 1.36 (1.02–1.82) 107 (3.3)/3123 (96.7) 1.16 (0.92–1.47)
Current BMI < 26.4 kg/m2 31 (4.1)/722 (95.9) 1.60 (1.10–2.32) 23 (5.3)/413 (94.7) 2.08 (1.35–3.18)
Current BMI ≥ 26.4 kg/m2 12 (4.8)/237 (95.2) 1.96 (1.10–3.51) 29 (4.4)/627 (95.6) 1.80 (1.22–2.65)
BC breast cancer; Units: age (1 year), BMI (5 units), BMI at age 20 (5 units), height (5 cm), age at menopause (1 year), exercise (1 h per week),
alcohol (1 unit per week), age at menarche (1 year); BMI median: 26.4 kg/m2, BMI age 20 median: 21.6 kg/m2.
3. Results
3.1. Flow Diagram
From the cohort of 57,902 women, 895 were diagnosed with breast cancer prior to
study entry, 4 were lost to follow up and were excluded from the analysis. Women with
unknown MHT use status were also excluded from the analysis (N = 514). The denominator
for the main analysis was 56,489 with the endpoint being a new diagnosis of breast cancer
(N = 1663, 3.2% of the cohort) (Figure 1).
3.2. Demographic Characteristics and Breast Cancer Risk Factors According to MHT Use
Demographic characteristics and BC risk factors according to MHT groups are shown
in Table 4. Of those eligible for analysis 7.8% were current MHT users, 28.6% were former
users and 63.6% had never used MHT. Across all MHT groups at study entry, 35.9% were in
the underweight or normal BMI category range, 39.5% in the overweight, 24.6% in the obese
BMI category, 3801 women had an unknown BMI. The median age at first pregnancy was
24 years (interquartile range [IQR] 21–28 years), 26.7% of women had their first pregnancy
either at or after the age of 30 years. In total, 27.9% of women had a first or second degree
family history of ovarian and/ or breast cancer.
When compared to never users, current MHT users had a higher percentage of
oophorectomy (27.5% vs. 5.6%), lower BMI at study entry (median: 26.0 vs. 26.4 kg/m2),
were less likely to have a family history of ovarian and/ or breast cancer (26.6% vs. 28.3%),
a lower deprivation score (median: 17.6 vs. 19.4), and younger age of first pregnancy
(median 23 vs. 24 years). As expected, former users were the oldest group, also reflected
by the higher percentage of participants being postmenopausal.
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Table 4. Baseline Characteristics of the 56,489 women in the PROCAS cohort (2009–2015).
Status of MHT Use
Total Never Former Current
Number of women (%) 56,489 (100) 35,933 (63.6) 16,149 (28.6) 4407 (7.8)
Ethnicity
White 53,571 (94.8) 33,695 (93.8) 15,634 (96.8) 4242 (96.3)
Other 2918 (5.2) 2238 (6.2) 515 (3.2) 165 (3.7)
Unknown 1799 1027 648 124
Age at study entry
Median (IQR) 56.9 (51.6–63.6) 53.9 (50.7–60.8) 62.9 (58.3–66.6) 55.2 (51.5–60.6)
Mean (SD) 57.8 (7.0) 56.0 (6.7) 62.3 (5.8) 56.4 (6.0)
Menopausal status
premenopausal and perimenopausal 18,764 (33.2) 16,742 (46.6) 821 (5.1) 1201 (27.3)
postmenopausal 37,725 (66.8) 19,191 (53.4) 15,328 (94.9) 3206 (72.7)
Unknown 2831 2673 76 82
Age at menopause
Median (IQR) 50.0 (46.0–53.0) 50.0 (48.0–53.0) 50.0 (45.0–53.0) 48.0 (44.0–51.0)
Mean (SD) 49.0 (5.6) 49.9 (4.7) 48.1 (6.4) 47.1 (6.6)
Unknown 46 (0.1) 29 (0.1) 15 (0.1) 2 (<0.1)
Age at menarche
Median (IQR) 13.0 (12.0–14.0) 13.0 (12.0–14.0) 13.0 (12.0–14.0) 13.0 (12.0–14.0)
Mean (SD) 12.9 (1.6) 12.9 (1.6) 12.8 (1.6) 12.9 (1.6)
Unknown 1186 (2.1) 762 (2.1) 319 (2.0) 105 (2.4)
Parity and age at first pregnancy
Nulliparous 7330 (13.0) 5028 (14.0) 1681 (10.4) 621 (14.1)
<30 41,408 (73.3) 25,259 (70.2) 13,013 (18.5) 3236 (73.4)
≥30 7751 (13.7) 5706 (15.8) 1455 (2.2) 550 (12.5)
Median age at first pregnancy (IQR) 24.0 (21.0–28.0) 24.0 (21.0–28.0) 23.0 (20.0–26.0) 23.0 (20.0–27.0)
Mean age at first pregnancy (SD) 24.4 (5.3) 25 (5.3) 23.5 (4.6) 24.1 (5.2)
Unknown 4 (<0.1) 3 (<0.1) 1 (<0.1) 0 (<0.1)
BMI
Underweight or normal weight (<25 kg/m2) 20,216 (35.9) 12,931 (36.1) 5486 (34.1) 1799 (41.0)
Overweight (25–29.9 kg/m2) 22,249 (39.5) 13,813 (38.5) 6660 (41.4) 1776 (40.4)
Obese (≥30 kg/m2) 13,868 (24.6) 9091 (25.4) 3959 (24.6) 818 (18.6)
Median (IQR) 26.4 (23.8–29.9) 26.4 (23.7–30.0) 26.4 (24.0–29.9) 26.0 (23.4–28.7)
Mean (SD) 27.4 (5.4) 27.5 (5.5) 27.4 (5.1) 26.5 (4.7)
Unknown 3801 2587 933 281
BMI at age 20
Underweight or normal weight (<25 kg/m2) 50,119 (88.8) 31,673 (88.2) 14,456 (89.6) 3990 (90.6)
Overweight (25–29.9 kg/m2) 5105 (9.0) 3369 (9.4) 1388 (8.6) 348 (7.9)
Obese (≥30 kg/m2) 1243 (2.2) 877 (2.4) 298 (1.8) 68 (1.5)
Median (IQR) 21.6 (20.3–23.0) 21.6 (20.3–23.2) 21.6 (20.2–23.0) 21.6 (20.0–22.8)
Mean (SD) 22.0 (3.1) 22.1 (3.1) 21.9 (2.9) 21.8 (2.9)
Unknown 6777 4694 1600 483
Mean Height (SD) 1.62 (0.07) 1.62 (0.07) 1.61 (0.06) 1.62 (0.06)
Median Height (IQR) 1.63 (1.57–1.65) 1.63 (1.57–1.65) 1.60 (1.57–1.65) 1.63 (1.57–1.68)
Unknown 1111 766 269 76
Oophorectomy
Yes 6696 (12.0) 1999 (5.6) 3584 (22.2) 1213 (27.5)
No 49,693 (88.0) 33,934 (94.4) 12,565 (77.8) 3194 (72.5)
Unknown 8709 5183 2716 810
MHT type
Oestrogen only 8895 (43.2) 6617 (41.0) 2278 (51.7)
Combined 11,661 (56.7) 9532 (59.0) 2129 (48.3)
Unknown 13,456 12,441 1015
Duration of MHT use (years)
Median (IQR) 5 (2.0–10.0) 5 (2.0–10.0) 7 (2.5–13.0)
Mean (SD) 7.3 (4.6) 6.2 (5.4) 8.6 (7.2)
Unknown 2433 1178 1255
VAS Density
Median (IQR) 24.8 (14.9–35.8) 24.8 (15.6–35.8) 22.4 (12.9–34.4) 29.5 (18.9–41.0)
Mean (SD) 27.1 (16.2) 27.5 (16.1) 25.3 (15.8) 31.3 (16.8)
Family History of Breast and/ or Ovarian Cancer *
Yes 15,738 (27.9) 10,185 (28.3) 4379 (27.1) 1174 (26.6)
No 40,748 (72.1) 25,748 (71.7) 11,768 (72.9) 3232 (73.4)
Median exercise hours per week (IQR) 3.5 (1.5–7.0) 3.5 (1.0–6.0) 3.5 (2.0–8.0) 3.5 (2.0–7.0)
Unknown 17,085 11,171 4630 1284
Median alcohol units per week (IQR) 4.0 (0.0–10.0) 4.0 (0.0–10.0) 4.0 (0.0–10.0) 4.0 (1.0–10.0)
Unknown 2512 1593 723 196
Median EIMD score 2010 (IQR) ** 18.9 (10.4–35.1) 19.4 (10.5–35.4) 18.7 (10.6–34.9) 17.6 (9.7–32.5)
Unknown 312 176 111 25
BMI body mass index, SD standard deviation, IQR interquartile range; MHT hormonal replacement therapy, VAS visual analogue scale;
EIMD English Index of multiple deprivation. * First or second degree relative with ovarian and/ or breast cancer; ** Ever vs. never MHT
EIMD 2010 p = 0.002, EIMD current vs. never p < 0.001, never vs. former p = 0.444; age adjusted comparisons: BMI current vs. never
p < 0.001, never vs. former p = 0.639; age adjusted VAS current vs. never p < 0.001, never vs. former p = 0.697; age, menopausal status, BMI
adjusted VAS current vs. never p < 0.001, never vs. former p = 0.001.
Compared with former users, current users were younger (median: 55.2 vs. 62.9 years),
had longer use of MHT (median: 7 vs. 5 years), higher percentage use of oestrogen only
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MHT (51.7% vs. 41.0%), lower BMI at entry (median: 26.0 vs. 26.4 kg/m2), were less
likely to have family history of breast and/ or ovarian cancer (26.6% vs. 27.1%), and lower
deprivation score (median: 17.6 vs. 18.7). All differences cited have p < 0.001 due to large
sample size. Women with known MHT status were lighter at entry to PROCAS, more likely
to be white, and from less deprived backgrounds than those with unknown MHT status
(Table S3).
3.3. MHT Use Status and Breast Cancer Risk
Median follow up from study entry was 8 years (IQR: 7–9, minimum 5 and maximum
12 years). Compared with never use, current MHT use was positively associated with
breast cancer (HR 1.35, 95% CI 1.13–1.60), while there was little evidence of an association
for former users (HR 1.03, 95% CI 0.91–1.17) (Table 5). The fully adjusted model fit is shown
in Table S1b.
Table 5. MHT status and type of MHT and breast cancer risk.
MHT Use Status N% BC/ N% no BC HR (95% CI) p-Value HR (95% CI) p-Value
Never 998 (2.8)/ 34,397 (97.2) 1.00 1.00
Former 507 (3.2)/ 15,366 (96.8) 0.98 (0.88–1.10) 0.765 1.03 (0.91–1.17) 0.614
Current 158 (3.6)/ 4182 (96.4) 1.27 (1.07–1.50) 0.006 1.35 (1.13–1.60) 0.001
MHT type
Never 998 (2.8)/ 34,397 (97.2) 1.00 1.00
Former oestrogen only 191 (2.9)/ 6334 (97.1) 0.90 (0.76–1.05) 0.189 0.95 (0.79–1.14) 0.558
Former combined 316 (3.4)/ 9032 (96.6) 1.04 (0.91–1.19) 0.586 1.06 (0.93–1.22) 0.398
Current oestrogen only 63 (2.8)/ 2183 (97.2) 0.96 (0.74–1.24) 0.754 1.03 (0.79–1.34) 0.835
Current combined 95 (4.5)/ 1999 (95.5) 1.60 (1.30–1.98) <0.001 1.64 (1.32–2.03) <0.001
BC breast cancer, HR hazard ratio, CI confidence interval. Fully adjusted for age at consent (1 year), BMI (5 units), BMI at age 20 (5 units),
height (5 cm), age at menarche (1 year), age at menopause (1 year), menopausal status (pre/perimenopausal vs. postmenopausal),
ethnicity (white vs. other), alcohol consumption (1 unit/week), exercise (1 h/week), age at first pregnancy (<20, 20–24, 25–29, 30–34, ≥35),
oophorectomy (yes vs. no), family history (yes vs. no).
Breast cancer risk was highest in current users of combined MHT (n = 2129) (HR 1.64,
95% CI 1.32–2.03), compared with never users. Risk amongst current users of oestrogen
only was (n = 2278) (HR 1.03, 95% CI 0.79–1.34) compared with never users (Table 5).
Analysis was repeated for ER+ breast cancers only, which comprised 88% of breast
cancer diagnoses in the cohort. Current MHT users (combined and oestrogen only) were at
increased risk of an ER+ diagnosis BC (HR 1.45, 95% CI 1.20–1.74) (Table S1c).
3.4. Current BMI and MHT and Breast Cancer Risk
Current BMI was positively associated with breast cancer risk (adjusted HR 1.23 per
5 kg/m2, 95% CI 1.16 to 1.30; Table S1). The effect of MHT in current users was attenuated
by BMI (adjusted interaction 0.81, 95% CI 0.67 to 0.98; Table S1b). This is illustrated by
the data in Table 1 Part A, where there is less difference in risk between never and current
users of MHT in the higher BMI category than the lower BMI category.
3.5. Early Adulthood BMI and MHT and Breast Cancer Risk
BMI in young adulthood was inversely associated with breast cancer risk (adjusted
HR 0.77 per 5 kg/m2, 95% CI 0.69 to 0.87; Table S1b). BMI at age 20 did not attenuate risk
of current MHT use (adjusted interaction 1.05, 95% CI 0.72 to 1.53; Table S1). Table 1 Part B
shows high early BMI reduced risk across never, former and current users of MHT, MHT
did however increase risk across women with early BMI above and below the median.
3.6. Combined Stratified Model with Current BMI, Early BMI and MHT and Breast Cancer Risk
Risk of breast cancer amongst MHT users was stratified for ≥ and < median for
current BMI (26.4 kg/m2) and ≥ and < median for BMI age 20 years (21.6 kg/m2) (Table 1
Part C).
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Higher BMI at age 20 appears to attenuate the effects of high current BMI on BC risk
both amongst women who are not using MHT and amongst current MHT users (adjusted
interaction BMI *BMI 20 HR 0.96, 95% CI 0.90–1.02; Table S1).
There is no specific interaction between MHT use, current BMI and early BMI (HR
0.99, 95% CI 0.74–1.31) (Table S2c). Risk was highest amongst MHT users with current BMI
higher than the median and BMI at 20 less than the median (HR 1.84, 95% CI 1.22–2.76)
(Table 1c). Analysis for ER+ breast cancer found comparable results to the overall analysis
(Table S2d).
3.7. Effects of Oestrogen Only and Combined MHT and Current and Early BMI and Breast
Cancer Risk
Current combined MHT use increased risk amongst women irrespective of their
current and early adulthood BMI (Table 3 Part A). Oestrogen only MHT use did not
significantly increase risk in current or former MHT users in any of the BMI groups
(Table 3 parts A, B, and C). However, risk appeared lower amongst current users of oestro-
gen only MHT with early BMI > median (HR 0.67, 95% CI 1.45–1.00) compared to early
BMI < median (HR 1.23, 95% CI 0.87–1.73) (Table 3 Part B). Attenuation of risk amongst
current oestrogen only MHT users with current BMI > median is seen in women who also
had early BMI > median (HR 0.75, 95% CI 0.44–1.28) compared to women with early BMI <
median (HR 1.68, 95% CI 0.97–2.90) (Table 3 Part C).
3.8. MHT Use and Age at First Pregnancy
Women who had a late pregnancy had an increased risk of breast cancer (age of
first pregnancy >35 years HR 1.38, 95% CI 1.08–1.76) (Table S1b). Late first pregnancy or
nulliparity increased risk across MHT users and non-users (Table 2). There is no specific
interaction between MHT use, age of pregnancy or nulliparity (HR 1.00, 95% CI 0.80–1.02)
(Table S4).
3.9. Effects of Oestrogen Only and Combined MHT and Age of First Pregnancy
Risks were comparable with combined MHT use amongst women with age of first
pregnancy <30 years (HR 1.74, 95% CI 1.34–2.25) and > age 30 or nulliparity (HR 1.90, 95%
CI 1.16–3.13). However, risks appeared lower amongst current oestrogen only MHT users
with age of first pregnancy <30 years (HR 0.96, 95% CI 0.71–1.31) compared to >age 30 or
nulliparity (HR 1.81, 95% CI 0.93–3.53) (Table 2).
4. Discussion
In this cohort, women with a lower current BMI were more likely to be current MHT
users compared to women with a higher BMI. We have confirmed that current use of
MHT increases breast cancer risk with excess risk mainly attributed to use of combined
MHT. Higher early adulthood BMI had a small reduction in risk across never, former
and current MHT groups. Late first pregnancy or nulliparity increased risk across never,
former and current use of MHT groups. Neither BMI at age 20 or late first pregnancy or
nulliparity had a specific modifying effect on the breast cancer risk related to overall MHT
use. Observations of lower risks with oestrogen only MHT amongst women with high
early BMI and early age of first pregnancy are interesting and require further study in
larger cohorts.
Previous studies have reported that women with higher BMI were less likely to have
used MHT [14–16]. Possible reasons for less use of MHT by heavier women include: ex-
periencing fewer menopausal symptoms although this seems unlikely as the majority of
papers report increased vasomotor symptoms in heavier women [17,18]; reduced likeli-
hood of heavier women engaging with health behaviours, and contra-indications to MHT
prescription associated with higher risk of thrombosis [19].
Our findings of increased breast cancer risk with current combined MHT, particularly
with ER+ cancers concur with those found by the Collaborative Group [2]. We did not
however observe an increased breast cancer risk for former MHT users. There was no
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significant association with oestrogen only MHT and BC risk, however our reported
confidence intervals of the HR for oestrogen only MHT overlap with that reported by the
Collaborative Group, indicating the results are broadly similar.
In these analyses we observed that higher current BMI attenuates the BC risk associ-
ated with overall current (combined and oestrogen only) MHT use. The attenuation of BC
risk associated with oestrogen only MHT amongst currently heavier women has previously
been reported [2]. Postmenopausal oestrogen levels correlate with BMI since endogenous
oestrogen synthesis occurs within adipose tissue. The observed attenuation of oestrogen
MHT risk is thought to reflect that exogenous oestrogen do not further stimulate the breast
tissue in heavier women. This is consistent with a previous stated model that proposes
a threshold for free oestrogen concentration beyond which there is no additional risk of
breast cancer [20].
The stratified analysis in the current study suggests the attenuation that effects of
oestrogen only MHT amongst currently heavier women is mainly seen in women who
were heavier at an early age, and are not seen in formerly lighter women. The confidence
intervals of these associations are quite wide due to small numbers of current users.
However this observation raises the possibility that the apparent attenuation of oestrogen
only MHT breast cancer risk amongst currently heavier women may be related to early
rather than current BMI effects. Previous reports summarised in the collaborative overview
did not examine the effects of early BMI.
A previous analysis within the PROCAS cohort reported that for women with early
adulthood BMI >23.4 kg/m2 (top 25% centile) neither attained adult BMI nor adult
weight gain was associated with breast cancer risk [8]. The observation that higher BMI
in early adulthood attenuates the BC risk associated with later adiposity has been re-
ported in a number of studies [21–23]. A significant part of BC risk associated with
postmenopausal BMI is thought to be mediated by increased oestrogen levels and the asso-
ciated stimulation of breast tissue proliferation [24]. Reduced breast tissue proliferation
has been reported amongst pre and postmenopausal women who had been heavier at age
18 (BMI >22 kg/m2) [25]. Higher early adulthood BMI may attenuate the proliferative
response of breast tissue to endogenous (associated with current BMI) or exogenous (MHT)
oestrogen through a number of mechanisms. These include reducing terminal end buds
and ductal elongation, and an overall reduction in the number of cells within breast tis-
sue [25–27] and decreased expression of genes involved with both oestrogen action, i.e.,
ESR1 and GATA3, and cell proliferation, i.e., RPS6KB1, in breast tissue [28]. Also, increased
levels of bioavailable oestrogens in early adulthood (associated with insulin levels and
decreased sex hormone binding globulin) [29] could induce earlier differentiation of mam-
mary cells [30] and expression of the BRCA1 tumour suppressor gene [31]. Higher levels
of insulin-like growth factor 1 (IGF-1) during childhood and adolescence are associated
with lower levels in adulthood [32]. The synergistic effects and cross talk between IGF-1
and oestrogen and their receptors are well established [33]. In addition women who are
heavier in early adulthood are likely to have greater numbers of adipocytes (a hyperplastic
phenotype). In contrast formerly lean women who gain weight will develop adipose hy-
pertrophy (few but large cells) which are associated with inflammation and dysregulated
metabolism [34].
A prospective study among 483,241 women and 7656 breast cancers studied whether
MHT-associated BC risk is modified by life course patterns of BMI. The study reported
that current users of MHT who reported being overweight at the ages of 7 and 15 (self-
identified as being heavier than their peers) were at higher risk (HR 1.68, 95% CI 1.32–2.14)
compared to never users of MHT who were overweight as young. However, risks were
higher amongst current MHT users who remained at normal weight throughout adult life
(HR 2.25, 95% CI 1.93–2.62) or who had gained weight (HR 2.28, 95% CI 1.94–2.67) [35].
The authors reported these risks were higher than expected when adding the separate risks
of BMI and MHT with respective relative excess risk due to the interaction scores of 0.52
(95% CI 0.09–0.95) and 0.37 (95% CI -0.07 – +0.08). They concluded that women who were
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overweight at a young age were less susceptible to the effects of MHT than women who
remained a normal weight or who gain weight in adulthood. This effect was seen amongst
the whole cohort (70% combined MHT and 23% oestrogen only) and within the combined
only group. They did not report the associations amongst current oestrogen only MHT
users. The findings from this large cohort are of interest, however the analyses of early
weight did not adjust for current BMI. Since higher weight at a younger age is likely to
result in a higher current BMI, this study may not distinguish any interactions between
early weight and current BMI and the effects of MHT.
We found that late age at first pregnancy increased risk amongst never, current and
former MHT users. Age at first pregnancy does not modify risk associated with overall
MHT use and breast cancer. Oestrogen only MHT appeared to be associated with a greater
risk amongst women with a late first pregnancy or nulliparity compared to women with
age of first pregnancy <30. There was no modification of the risk of combined MHT.
Risk of late pregnancy relates to a prolonged duration of undifferentiated state of
the mammary tissue [36]. Synergistic effects of nulliparity and high postmenopausal BMI
on BC risk in women aged >70 years have been reported [37]. Murrow et al recently
reported that parity and high BMI amongst premenopausal women both decreased the
oestrogen and progesterone responsiveness of the breast. These effects were associated
with respective reductions in hormone signalling in hormone responsive luminal cells and
reductions in the proportion of hormone responsive luminal cells within the mammary
epithelium [10]. This data suggests a common pathway that could be shared between early
pregnancy and high young age adiposity that is protective against breast cancer.
Our stratified analysis aimed to study the independent and combined interactions of
current BMI, early BMI, MHT use and BC risk. Also whether these interactions differed
with combined and oestrogen only MHT. Our sample size limits the ability to study all of
these relationships with sufficient power. The observed trends in higher early weight and
early pregnancy reducing the risk of oestrogen only MHT breast cancer requires further
investigation in larger cohort or consortium studies.
Strengths of this analysis are that it was conducted in a large UK population. Many
confounders associated with breast cancer risk were taken into consideration. The indepen-
dent effects of both current BMI and early adulthood BMI were elicited in the models by
including BMI at two different time points. Additionally, detailed information regarding
MHT use and type were collected and breast cancer diagnosis updated on a regular basis.
Sensitivity analysis showed that the models were consistent.
All information used in this analysis were self-reported, including current weight,
height, weight at age 20, age at first pregnancy, name of MHT, how long MHT was used
for and when MHT was stopped for former users. It is well known that there is a bias of
underreporting weight and over reporting height [38]. However validation studies show
self-reported BMI is highly correlated with independently measured weight and the mean
difference between self-reported and measured weight is minimal [8,39]. BMI at entry and
at age 20 was missing for 7.0% and 12.4% of the study population respectively. Recall bias
could also occur for variables such as MHT duration. We did not update HRT usage status
during follow up, and so were unable to estimate any association between duration of HRT
use and risk of BC. The median value of the cohort was assumed where data was missing,
and other methods could be used to account for the missing values. Breast cancer risk
varies across racial groups [40] and the majority of women in the study were Caucasian
thus limiting generalization of the findings to other ethnic groups. Risk factor information
was only collected at baseline and it is possible that MHT status, BMI and other risk factors
changed for some women. Some current MHT users are likely to have become former users
and premenopausal women who had not used MHT could have become postmenopausal
and started using MHT during the eight years of follow up.
Implications for practice for this research include that clinical risk assessment of
suitability of a woman to commence on MHT, should include consideration of their current
BMI and potentially early adulthood BMI and the type of MHT to be prescribed. The
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findings of this study support recommendations to maintain a healthy weight across the
life course. Breast cancer risk is similar among women with higher current BMI who never
used MHT and women with lower BMI who use MHT. The smaller increase in risk with
MHT amongst heavier women should not deter these women from losing weight. The
highest BC risk is seen amongst current MHT users with a high current BMI, especially
those with a low BMI at an early age. Women at increased weight taking MHT will have
higher risks of other MHT associated adverse effects including venous thromboembolism,
stroke and endometrial cancer [5]. Weight loss has been shown to decrease risk of other
cancers including colorectal and endometrial cancer, and additionally might help manage
menopausal symptoms [41].
Future studies need to investigate the associations between current and early BMI and
age of pregnancy and MHT associated breast cancer risk. These studies could determine
whether there are specific BMI ranges where these effects occur and whether the range is
different within different ethnic groups.
5. Conclusions
Combined oestrogen and progestagen MHT was associated with the highest BC risk.
This risk was not modified by early or current BMI and age of pregnancy. Exploratory
analysis amongst oestrogen only MHT users showed an attenuation of risk with early BMI
greater than or equal to the median compared to less than the median and with age of first
pregnancy less than 30 years compared to equal or greater than age 30 or nulliparity which
require further study. Identifying characteristics which modify a woman’s MHT associated
BC risk will allow their individual risks and benefits to be assessed and appropriate
prescription of MHT to manage troublesome menopausal symptoms.
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